KLK3 and cancer: Although PSA testing has resulted in a decrease in cancer stage and grade at detection [5, 6], its benefits regarding prostate cancer mortality remain unresolved, with contradictory findings from two randomised controlled trials, after 13 years follow-up [7, 8].